Home » Newsletters » BioWorld Science

BioWorld Science

May 15, 2012

View Archived Issues

EMERGE study results presented for pegylated interferon lambda-1a

Gene therapy rescues retinal degeneration in Prom1 knockout mice

Gene therapy shows promise for retinal degeneration

GlaxoSmithKline patents novel CRAC inhibitors

U.S. team develops new immunogenic polypeptides for HIV infection

Lupin synthesizes novel voltage-gated sodium channel blockers

Merck KGaA designs new MetAP 2 inhibitors

Presidio Pharmaceuticals discloses new compounds targeting NS5A protein

Biomarkers of inflammation are associated with AMD severity

S1 Biopharma expands focus

Early clinical data for ABT-267 monotherapy and combination treatment shows promise

Biovest plans to seek European marketing approval for cancer vaccine

New phase III Lu-AA-21004 data in MDD support planned regulatory filings

Bristol-Myers Squibb establishes first discovery collaboration in China

Newron completes phase III program for safinamide, signs new licensing agreement

Maxygen to receive payment from Bayer HealthCare for factor VIIa program

Resminostat enters clinical development in Japan

KineMed and CHDI Foundation enter biomarker collaboration

Livatag begins phase III trial for liver cancer

Fibrocell Science submits protocol to FDA for azficel-T study

Cyclacel gives update on phase II/III sapacitabine study

IDRI finds partner for tuberculosis vaccine candidate

Scil Proteins enters into collaboration with Ono Pharmaceutical

L-DOS-47 begins phase I/II study for NSCLC

Furiex enters into licensing agreements for Priligy

Popular Stories

Bio Korea 2026 kicks off with spotlight on oligonucleotides
BioWorld
Three decades of trial-and-error, and the resulting safety data, in the oligonucleotide-based therapeutic space have paved way for the present-day innovations and...
University of Western Australia patents 5-HT2A/B modulators
BioWorld Science
University of Western Australia has identified new lysergic acid diethylamide (LSD) analogues acting as 5-HT2A and 5-HT2B modulators reported to be useful for the...
AA meeting of minds as PTC, Novartis push votoplam in HD
BioWorld
What PTC Therapeutics Inc.’s latest data with votoplam might mean in the Huntington’s disease (HD) landscape became grist for Wall Street after the firm unveiled...
Innervation can slow, as well as speed, tumor growth, study finds
BioWorld
Innervation by the sympathetic nervous system is typically a boon to tumors. But researchers from Weill Cornell Medicine and colleagues have shown that in some...
Alceptor Therapeutics discovers new α2B-adrenoceptor agonists
BioWorld Science
Alceptor Therapeutics Inc. has patented new pyrazol-5-amine α2B-adrenoceptor agonists reported to be useful for the treatment of pain and hypertension.